Rhumbline Advisers Guardant Health, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Guardant Health, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 163,701 shares of GH stock, worth $5.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

163,701

Previous 173,298 5.54%

Holding current value

$5.34 Million

Previous $5 Million 25.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$22.3 - $36.29 $214,013 - $348,275	-9,597 Reduced 5.54%	163,701 $3.75 Million
Q2 2024 Aug 01, 2024	BUY	$16.07 - $31.84 $163,303 - $323,558	10,162 Added 6.23%	173,298 $5 Million
Q1 2024 May 09, 2024	BUY	$17.13 - $26.91 $66,635 - $104,679	3,890 Added 2.44%	163,136 $3.37 Million
Q4 2023 Feb 08, 2024	SELL	$21.58 - $29.5 $8,934 - $12,213	-414 Reduced 0.26%	159,246 $4.31 Million
Q3 2023 Nov 09, 2023	BUY	$25.8 - $39.97 $224,150 - $347,259	8,688 Added 5.75%	159,660 $4.73 Million
Q2 2023 Aug 08, 2023	BUY	$20.94 - $38.01 $613,856 - $1.11 Million	29,315 Added 24.1%	150,972 $5.4 Million
Q1 2023 May 11, 2023	BUY	$22.92 - $33.76 $261,425 - $385,066	11,406 Added 10.35%	121,657 $2.85 Million
Q4 2022 Feb 14, 2023	BUY	$25.44 - $59.78 $104,278 - $245,038	4,099 Added 3.86%	110,251 $3 Million
Q3 2022 Nov 10, 2022	BUY	$43.66 - $61.0 $372,681 - $520,696	8,536 Added 8.74%	106,152 $5.71 Million
Q2 2022 Aug 11, 2022	BUY	$28.82 - $77.35 $460,024 - $1.23 Million	15,962 Added 19.55%	97,616 $3.94 Million
Q1 2022 May 12, 2022	SELL	$48.25 - $100.49 $220,888 - $460,043	-4,578 Reduced 5.31%	81,654 $5.41 Million
Q4 2021 Feb 10, 2022	BUY	$88.71 - $120.43 $240,226 - $326,124	2,708 Added 3.24%	86,232 $8.63 Million
Q3 2021 Nov 12, 2021	SELL	$98.77 - $132.17 $69,929 - $93,576	-708 Reduced 0.84%	83,524 $10.4 Million
Q2 2021 Aug 05, 2021	SELL	$109.77 - $165.68 $29,418 - $44,402	-268 Reduced 0.32%	84,232 $10.5 Million
Q1 2021 May 06, 2021	SELL	$127.04 - $179.1 $324,206 - $457,063	-2,552 Reduced 2.93%	84,500 $12.9 Million
Q4 2020 Feb 10, 2021	BUY	$99.96 - $135.93 $535,585 - $728,312	5,358 Added 6.56%	87,052 $11.2 Million
Q3 2020 Nov 12, 2020	SELL	$80.32 - $111.8 $373,086 - $519,311	-4,645 Reduced 5.38%	81,694 $9.13 Million
Q2 2020 Aug 13, 2020	BUY	$60.49 - $97.5 $2.94 Million - $4.73 Million	48,550 Added 128.48%	86,339 $7.01 Million
Q1 2020 May 06, 2020	BUY	$59.04 - $88.81 $56,973 - $85,701	965 Added 2.62%	37,789 $2.63 Million
Q4 2019 Feb 05, 2020	BUY	$59.49 - $82.78 $58,478 - $81,372	983 Added 2.74%	36,824 $2.88 Million
Q3 2019 Oct 23, 2019	BUY	$62.59 - $110.3 $96,263 - $169,641	1,538 Added 4.48%	35,841 $2.29 Million
Q2 2019 Aug 14, 2019	BUY	$63.94 - $91.11 $898,740 - $1.28 Million	14,056 Added 69.42%	34,303 $2.96 Million
Q1 2019 May 01, 2019	BUY	$34.3 - $97.98 $12,588 - $35,958	367 Added 1.85%	20,247 $1.55 Million
Q4 2018 Jan 31, 2019	BUY	$29.2 - $46.1 $580,496 - $916,468	19,880 New	19,880 $747,000

Others Institutions Holding GH

# of Institutions

323

Shares Held

127M

Call Options Held

844K

Put Options Held

2.38M

View Full List

About Guardant Health, Inc.

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $3.34B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

More about GH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Guardant Health, Inc. Transaction History